Skip to main content

Table 2 Additional analyses to calculate the ACDW threshold for the occurrence of subjective neurological symptoms

From: Peripheral neuropathy induced by drinking water contaminated with low-dose arsenic in Myanmar

 

Symptom

< 10 ppb

≥ 10 ppb

P

< 50 ppb

≥ 50 ppb

P

All participants (≥ 5 years old, N = 1867)

 Smell defects

Yes

13 (1.4)

14 (1.5)

0.497

24 (1.6)

3 (0.9)

0.230

No

922

918

1495

345

 Visual defects

Yes

298 (31.9)

288 (30.9)

0.344

486 (32.0)

100 (28.7)

0.132

No

637

644

1033

248

 Taste defects

Yes

12 (1.3)

19 (2.0)

0.137

23 (1.5)

8 (2.3)

0.207

No

923

913

1496

340

 Hearing defects

Yes

63 (6.7)

68 (7.3)

0.351

109 (7.2)

22 (6.4)

0.334

No

872

864

1410

324

 Feeling of weakness

Yes

122 (13.0)

164 (17.6)

0.004**

232 (15.3)

54 (15.5)

0.483

No

813

768

1287

294

 Chronic numbness or pain

Yes

191 (20.4)

230 (24.7)

0.016*

342 (22.5)

79 (22.7)

0.495

No

744

702

1177

269

Children (5–15 years old, n = 456)

 Smell defects

Yes

0 (0)

0 (0)

 

0 (0)

0 (0)

 

No

240

216

366

90

 Visual defects

Yes

8 (3.3)

5 (2.3)

0.358

12 (3.3)

1 (1.1)

0.237

No

232

211

354

89

 Taste defects

Yes

0 (0)

0 (0)

 

0 (0)

0 (0)

 

No

240

216

366

90

 Hearing defects

Yes

2 (0.8)

3 (1.4)

0.451

3 (0.8)

2 (2.2)

0.257

No

238

213

363

88

 Feeling of weakness

Yes

8 (3.3)

5 (2.3)

0.358

10 (2.7)

3 (3.3)

0.490

No

232

211

356

87

 Chronic numbness or pain

Yes

9 (3.8)

7 (3.2)

0.486

11 (3.0)

5 (5.6)

0.190

No

231

209

355

85

  1. Numbers indicate the number of participants
  2. Numbers in parentheses indicate the percentage of “yes” participants in each ACDW group
  3. Statistical analyses were performed using the chi-square test. *P < 0.05, **P < 0.01, statistically significant difference
  4. Yes = present; no = absent